Should I Choose CAR T-Cell Therapy or Bispecific Antibodies After Myeloma Relapse?

Is CAR T therapy a breakthrough treatment for multiple myeloma?

Yes, CAR T is a major treatment advance for eligible adults with relapsed or refractory multiple myeloma, but “breakthrough” is not shorthand for “automatic best choice.” CARVYKTI is an individualized BCMA-directed therapy made from a patient's own genetically modified T cells and delivered as one intravenous infusion, according to the DailyMed prescribing information.

The FDA's 2025 CARVYKTI indication covers adults whose disease is relapsed or refractory after at least one prior treatment line including a proteasome inhibitor and an immunomodulatory drug, when the disease is refractory to lenalidomide. That is an eligibility framework, not a promise of benefit for every person.

The cleanest way to compare the evidence is to separate results from logistics. A 2024 Journal for ImmunoTherapy of Cancer meta-analysis pooled third-line-or-later studies and found a complete-response rate of 54% with BCMA-directed CAR T versus 35% with BCMA x CD3 bispecific antibodies; pooled overall-response rates were 83% versus 65%. Those are meaningful differences. They are also an indirect comparison, not a randomized trial that assigned similar patients to each treatment.

CAR T has a concentrated operational burden: collection, manufacturing, lymphodepleting treatment, infusion, and close follow-up. Bispecific therapy shifts the burden. It may begin without waiting for a custom cell product, but the care plan must manage infection risk over continued treatment. Neither burden is trivial. Make the team name which one your household can realistically carry.

Should CAR T be used before a bispecific antibody?

CAR T is often worth discussing before a bispecific antibody when disease control allows time for manufacturing, but sequencing must be individualized rather than treated as a universal rule. Disease pace is the first filter. A treatment that looks stronger on a chart is not automatically the right next move if myeloma needs control before a cell product can be ready.

The 2025 expert roundtable in Clinical Lymphoma, Myeloma and Leukemia reports that autologous CAR T manufacturing can take 4 to 8 weeks, or longer when the product does not meet manufacturing criteria. It describes bridging therapy as treatment used after leukapheresis and before lymphodepleting chemotherapy to control myeloma during that interval. In real-world reports cited by the authors, about 77% of people receiving ide-cel or cilta-cel received bridging therapy.

That creates the core sequencing question: can the disease be controlled safely while the CAR T process runs? The answer changes with tumor burden, prior therapies, toxicity risk, logistics, and how quickly the disease is moving, as the 2025 roundtable explains. This is the timing test: do not ask only, “Which treatment is better?” Ask, “What keeps the disease controlled while we reach the treatment with the intended payoff?”

Use exact language at the appointment: “Please compare CAR T first versus bispecific therapy first for my disease pace. What would make you change that order?” Then ask: “If we choose CAR T, what is the bridging plan, who owns it, and what result would trigger a new plan?” That reduces the cognitive load for everyone involved. It turns a broad recommendation into a decision path.

How long do I need to stay near a CAR T treatment center?

For outpatient cilta-cel programs described in the evidence, plan for an extended local stay, but confirm the exact rule with your own treatment center. A 2024 Frontiers in Immunology study reported that participating centers commonly required lodging within 30 minutes of the center for 30 days after infusion, while noting that actual requirements vary by program.

The same 2024 study described daily treatment-center visits for up to 14 days after outpatient cilta-cel infusion, followed by visits 2 to 3 times weekly for the following 2 weeks. It also identified caregiver education, urgent-access pathways, available inpatient beds, and affordable travel and lodging as access and safety issues. These are not side details. They determine whether a treatment plan works outside the clinic.

DailyMed's 2025 CARVYKTI label requires at least daily monitoring for cytokine release syndrome and neurologic toxicity for 7 days after infusion, with monitoring for cytokine release syndrome for at least 2 weeks. The label reported a median onset of 7 days for cytokine release syndrome across its cited studies. That delayed timing explains why “infusion day” is not the finish line.

Run the logistics rehearsal before committing. Ask the center: “Where must we stay, how often are visits expected, who can be the caregiver, and what happens after hours?” Ask a second version for your budget: “Which travel, lodging, and caregiver costs are our responsibility, and which support resources does your program offer?” Public sources in this dossier do not supply a universal cost figure, so a center-specific written estimate matters more than a guess.

What happens while CAR T cells are being manufactured?

While CAR T cells are manufactured, the team may use bridging therapy to keep the myeloma controlled between cell collection and the preparatory treatment before infusion. The 2025 Clinical Lymphoma, Myeloma and Leukemia roundtable states that this choice is tailored to disease pace, tumor burden, prior treatment, toxicity risk, and logistics.

The weak question is, “What are we doing while we wait?” The stronger question is, “What is the minimum treatment needed to control myeloma without undermining the CAR T plan?” The same 2025 expert discussion advises coordination with the CAR T specialty center and describes guidance for a washout of at least 1 week, or 5 drug half-lives when shorter, between bridging treatment and lymphodepleting chemotherapy. That is a planning constraint for the oncology team, not a self-managed timetable.

Ask for one page that lists the collection date, expected manufacturing window, bridging-treatment owner, monitoring contact, travel trigger, and contingency if the product is delayed or disease control changes. That document prevents the expensive kind of confusion: duplicated calls, missed handoffs, and a family learning too late that a caregiver or lodging requirement was non-negotiable.

Finish the visit with this assignment: “What are the next three decisions, what information changes each decision, and who calls us if the plan changes?” Write down the answers before leaving. In relapse care, clarity is not administrative polish. It is part of the treatment plan.